Related Experiment Video
Updated: Apr 15, 2026

06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
1.0K
Prognostic Survival Model Following Primary Radical Surgery for Early-Stage Cervical Cancer
Rattiya Phianpiset1, Chayanid Detwongya1, Manatsawee Manopunya1
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Cancers
|April 14, 2026
Summary
A new prediction model helps identify early-stage cervical cancer patients at high risk of recurrence after surgery. This tool aids clinicians in tailoring postoperative treatment for better patient outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Gynecologic Oncology
Background:
- Radical hysterectomy with pelvic lymphadenectomy is standard for early-stage cervical cancer.
- Disease recurrence remains a challenge despite optimal treatment.
- Need for better tools to stratify recurrence risk and guide postoperative management.
Purpose of the Study:
- Develop and validate a prediction model for recurrence risk in early-stage cervical cancer.
- Aid clinicians in tailoring postoperative treatment strategies.
- Improve patient outcomes by identifying high-risk individuals.
Main Methods:
- Retrospective analysis of data from 1309 women undergoing radical hysterectomy.
- Cox proportional hazard regression model developed using backward elimination.
- Internal validation via bootstrapping; performance assessed by C-index and calibration plots.
Main Results:
- 115 patients (8.8%) experienced recurrence; median follow-up was 72.2 months.
- Significant predictors of recurrence-free survival (RFS) included tumor size, histology, lymph node status, lymphovascular invasion, and platelet-to-lymphocyte ratio.
- The model showed good fit, calibration, and discriminative ability (C-index = 0.73).
Conclusions:
- The developed survival model is a valuable tool for therapeutic decision-making in early-stage cervical cancer.
- The model demonstrates robust predictive performance and calibration.
- External validation is recommended to confirm reproducibility across diverse patient populations.

